Sara Hall

List of Publications by Year
in descending order

31 papers	2,856 citations	430874 18 h-index	526287 27 g-index
32 all docs	32 docs citations	32 times ranked	4284 citing authors

#	Article	IF	Citations
1	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. JAMA Neurology, 2019, 76, 1035.	9.0	455
2	Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders. Archives of Neurology, 2012, 69, 1445.	4.5	407
3	Blood-based NfL. Neurology, 2017, 88, 930-937.	1.1	369
4	Cerebrospinal fluid inflammatory markers in Parkinsonâ€™s disease â€“ Associations with depression, fatigue, and cognitive impairment. Brain, Behavior, and Immunity, 2013, 33, 183-189.	4.1	214
5	Non-Motor Symptoms in Patients with Parkinsonâ€™s Disease â€“ Correlations with Inflammatory Cytokines in Serum. PLoS ONE, 2012, 7, e47387.	2.5	180
6	CSF biomarkers and clinical progression of Parkinson disease. Neurology, 2015, 84, 57-63.	1.1	178
7	Levels of cerebrospinal fluid Î±-synuclein oligomers are increased in Parkinsonâ€™s disease with dementia and dementia with Lewy bodies compared to Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2014, 6, 25.	6.2	169
8	<scp>L</scp>ongitudinal <scp>M</scp>easurements of <scp>C</scp>erebrospinal <scp>F</scp>luid <scp>B</scp>iomarkers in <scp>P</scp>arkinson's <scp>D</scp>isease. Movement Disorders, 2016, 31, 898-905.	3.9	136
9	Low CSF Levels of Both Î±-Synuclein and the Î±-Synuclein Cleaving Enzyme Neurosin in Patients with Synucleinopathy. PLoS ONE, 2013, 8, e53250.	2.5	123
10	Increased CSF biomarkers of angiogenesis in Parkinson disease. Neurology, 2015, 85, 1834-1842.	1.1	109
11	Cerebrospinal fluid concentrations of inflammatory markers in Parkinsonâ€™s disease and atypical parkinsonian disorders. Scientific Reports, 2018, 8, 13276.	3.3	104
12	The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimerâ€™s but Not Parkinsonâ€™s Disease or Dementia with Lewy Bodies. PLoS ONE, 2015, 10, e0135458.	2.5	85
13	Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson's disease. Neurobiology of Disease, 2020, 139, 104831.	4.4	49
14	Proinflammatory Cytokines Are Elevated in Serum of Patients with Multiple System Atrophy. PLoS ONE, 2013, 8, e62354.	2.5	40
15	Disease-specific structural changes in thalamus and dentatorubrothalamic tract in progressive supranuclear palsy. Neuroradiology, 2015, 57, 1079-1091.	2.2	37
16	Alterations of Diffusion Kurtosis and Neurite Density Measures in Deep Grey Matter and White Matter in Parkinsonâ€™s Disease. PLoS ONE, 2016, 11, e0157755.	2.5	35
17	Performance of Î±Synuclein RT-QuIC in relation to neuropathological staging of Lewy body disease. Acta Neuropathologica Communications, 2022, 10, .	5.2	31
18	Alteration of putaminal fractional anisotropy in Parkinsonâ€™s disease: a longitudinal diffusion kurtosis imaging study. Neuroradiology, 2018, 60, 247-254.	2.2	23

#	Article	IF	Citations
19	Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients. Alzheimer's Research and Therapy, 2015, 7, 63.	6.2	20
20	Diffusion Tensor MRI to Distinguish Progressive Supranuclear Palsy from Î±-Synucleinopathies. Radiology, 2019, 293, 646-653.	7.3	20
21	Low Levels of Soluble NG2 in Cerebrospinal Fluid from Patients with Dementia with Lewy Bodies. Journal of Alzheimer's Disease, 2014, 40, 343-350.	2.6	16
22	AÎ²1-15/16 as a Potential Diagnostic Marker in Neurodegenerative Diseases. NeuroMolecular Medicine, 2013, 15, 169-179.	3.4	13
23	Differential expression of cerebrospinal fluid neuroinflammatory mediators depending on osteoarthritis pain phenotype. Pain, 2020, 161, 2142-2154.	4.2	11
24	Structural and functional neuroimaging changes associated with cognitive impairment and dementia in Parkinson's disease. Psychiatry Research - Neuroimaging, 2021, 312, 111273.	1.8	11
25	Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization. Pain Reports, 2022, 7, e988.	2.7	8
26	The Neuroinflammatory Acute Phase Response in Parkinsonianâ€Related Disorders. Movement Disorders, 2022, 37, 993-1003.	3.9	8
27	Midsagittal corpus callosal thickness and cognitive impairment in Parkinson's disease. European Journal of Neuroscience, 2022, 55, 1859-1872.	2.6	5
28	O4â€10â€01: PLASMA NFL: A NEW BIOMARKER FOR DIFFERENTIAL DIAGNOSIS OF PARKINSONIAN DISORDERS. Alzheimer's and Dementia, 2016, 12, P357.	0.8	0
29	P3â€270: CEREBROSPINAL FLUID CONCENTRATIONS OF INFLAMMATORY MARKERS IN PARKINSON'S DISEASE AND ATYPICAL PARKINSONIAN DISORDERS. Alzheimer's and Dementia, 2018, 14, P1180.	0.8	0
30	Plasma phosphoâ€tau217 can detect Alzheimerâ€like pathology in Parkinsonâ€™s disease with dementia and dementia with Lewy bodies. Alzheimer's and Dementia, 2020, 16, e042468.	0.8	0
31	Inflammatory, degeneration and neuritic growth biomarkers predict cognitive decline and dementia in Parkinsonâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0